Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Straumann Holding    STMN   CH0012280076

STRAUMANN HOLDING

(STMN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Straumann Holding : There is still some upside potential

share with twitter share with LinkedIn share with facebook
share via e-mail
02/27/2019 | 03:30am EDT
long trade
Live
Entry price : 771CHF | Target : 900CHF | Stop-loss : 700CHF | Potential : 16.73%
Shares in Straumann Holding show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good.
Investors have an opportunity to buy the stock and target the CHF 900.
Chart STRAUMANN HOLDING
Duration : Period :
Straumann Holding Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 47% by 2021.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.
  • Sales forecast by analysts have been recently revised upwards.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • Based on current prices, the company has particularly high valuation levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.4 times its estimated earnings per share for the ongoing year.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart
Subsector Medical Equipment, Supplies & Distribution
1st jan.Capitalisation (M$)Investor Rating
STRAUMANN HOLDING36.44%13 696
ABBOTT LABORATORIES15.87%151 314
MEDTRONIC PLC9.11%134 116
STRYKER CORPORATION31.09%78 666
BECTON, DICKINSON AND COMPA..12.39%69 097
ESSILORLUXOTTICA6.79%56 495
BAXTER INTERNATIONAL INC.24.60%42 104
HOYA CORPORATION29.22%28 445
COLOPLAST31.11%25 578
ZIMMER BIOMET HOLDINGS16.27%24 781
IDEXX LABORATORIES52.80%24 551
Autres valeurs du secteur
Stocks mentioned in the article
ChangeLast1st jan.
STRAUMANN HOLDING -0.35% 843.2 Delayed Quote.36.44%
THOMSON REUTERS CORP 0.96% 88.64 Delayed Quote.33.17%

Ulrich Ebensperger
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (CHF)
Sales 2019 1 604 M
EBIT 2019 412 M
Net income 2019 334 M
Finance 2019 146 M
Yield 2019 0,75%
P/E ratio 2019 40,3x
P/E ratio 2020 32,7x
EV / Sales2019 8,23x
EV / Sales2020 7,05x
Capitalization 13 351 M
Upcoming event on STRAUMANN HOLDING
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 866  CHF
Last Close Price 843  CHF
Spread / Highest target 21,0%
Spread / Average Target 2,67%
Spread / Lowest Target -32,4%
EPS Revisions
Managers
NameTitle
Marco Gadola Chief Executive Officer
Gilbert Achermann Chairman
Gerhard Bauer Head-Research, Development & Operations
Peter Hackel Chief Financial Officer
Thomas Straumann Vice Chairman